3748-16-1

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, 6-hydroxy-2-(hydroxymethyl)(9CI) is used as a key intermediate for the production of various drugs. Its role in nucleic acid synthesis makes it a crucial component in the development of medications targeting genetic disorders and diseases.
Used in Agricultural Industry:
In the agricultural sector, 4(1H)-Pyrimidinone, 6-hydroxy-2-(hydroxymethyl)(9CI) serves as a building block for the synthesis of herbicides. Its involvement in the development of these chemicals helps in the management and control of unwanted plant growth, contributing to more efficient and productive agricultural practices.
Used as a Chemical Intermediate in Organic Synthesis:
4(1H)-Pyrimidinone, 6-hydroxy-2-(hydroxymethyl)(9CI) is utilized as a chemical intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications across various industries. Its versatility in synthesis processes highlights its importance in the field of chemistry.

InChI:InChI=1/C5H6N2O3/c8-2-3-6-4(9)1-5(10)7-3/h1,8H,2H2,(H2,6,7,9,10)

Upstream product

• 54198-71-9 2-hydroxy-acetamidine hydrochloride 
• 105-53-3 diethyl malonate 
• 623-50-7 ethyl 2-hydroxyacetate 
• 108-13-4 malonodiamide 

Relevant academic research and scientific papers

Discovery of a potent nicotinic acid receptor agonist for the treatment of dyslipidemia

Nicotinic acid has been used clinically for decades to control serum lipoproteins. Nicotinic acid lowers very low-density lipoprotein (VLDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and lipoprotein-a (LPa), and it is also effective in raising high-density lipoprotein (HDL)-cholesterol. However, nicotinic acid has several side effects in clinical use. The most notable is intense cutaneous vasodilation "flushing"+ on the upper body and face. We discovered a pyranopyrimidinedione series to be nicotinic acid receptor agonists. A potent nicotinic acid receptor agonist from this series {5-(3-cyclopropylpropyl)-2-(difluoromethyl)-3H-pyrano[2,3-d] pyrimidine-4,7-dione}with reduced flushing side effect in dogs was identified.

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

Identification, synthesis and pharmacological activity of moxonidine metabolites

The metabolism of moxonidine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5- pyrimidinamine, LY326869, in rats, mice, dogs, and humans has been examined. At least 17 metabolites were identified or tentatively identified in the different species by HPLC, LC/MS and LC/MS/MS. The identities of seven of the major metabolites have been verified by independent synthesis. The metabolites are generally derived from oxidation and conjugation pathways. Oxidation occurred at the imidazolidine ring as well as the methyl at the 2 position of the pyrimidine ring. All seven metabolites were examined in the spontaneously hypertensive rats (3 mg kg-1, i.v.) for pressure and heart rate. Only one, 2-hydroxymethyl-4-chloro-5-(imidazolidin-2-ylidenimino)-6-methoxypyrimidine, exerted a short-lasting decrease in blood pressure, albeit attenuated in magnitude compared to moxonidine.